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Abstract 
Aims:  
1. To develop a clozapine decision support tool (CDST). 
2. To evaluate the effectiveness of the CDST.   
 
 
Method: A CDST was developed, using current clozapine guidelines and evidence 
from published literature to support the inclusion of the different components of the 
tool. The CDST is a compilation of the latest recommendations and information 
aimed at assisting clinicians in making decisions that are in keeping with current 
guidelines. 
 
The study to evaluate the effectiveness of the CDST consisted of a pre- and post-
interventional audit, with the introduction of CDST in all clinical areas as the 
intervention, to assess the level of adherence to the clozapine guidelines by clinicians. 
The study population was made up of all patients at the study site who were on 
clozapine treatment during the study period. Data collection comprised of a clinical 
chart plus computer record audit and a prescribing audit that assessed adherence to the 
monitoring guidelines and prescribing guidelines respectively. 
 
Results: A total of 133 patient records were audited in the study with 67 in the pre-
interventional phase and 66 in the post-interventional phase. There was an overall 
general improvement in clinician adherence to guidelines with statistically significant 
improvements in monthly physical health monitoring (which can be attributed to the 
physical health monitoring prompt) and 6 monthly ECG performances.  
 
Conclusion: The results of this study indicate that introduction of the CDST as the 
intervention was responsible for the observed overall improvement in adherence by 
clinicians to the clozapine guidelines.  
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1 INTRODUCTION 
 
1.1 Background 
Clozapine is a second generation antipsychotic (SGA) reserved for treatment resistant 
schizophrenia. It was voluntarily withdrawn globally by the manufacturer in 1975 due 
to a few reported deaths which were linked to the side effect of agranulocytosis, 
which it causes. It was re-introduced in the early 1990s because it was shown to be 
clinically superior to the first generation antipsychotics (FGAs) in treatment resistant 
schizophrenia1. Agranulocytosis was already established as a major side effect of 
clozapine therapy which prompted mandatory haematological monitoring with its 
reintroduction2.  Since then there has been a growing body of evidence globally to 
support the inclusion of other monitoring parameters such as the physical 
observations of temperature, weight and waist measurements, respiration, bowel 
habits fasting serum glucose and serum lipids3,4,5,6,7. In support of this is the National 
Institute for Clinical Excellence (NICE) schizophrenia guideline recommendation for 
ongoing, routine physical health screening of all patients taking antipsychotic 
medication8. In addition, at initiation there is the requirement of patient registration 
with a clozapine monitoring centre and patient consent to the ongoing haematological 
and physical monitoring. Currently there is a lack of a systematic and uniform 
approach with regards to physical health monitoring in mental health facilities 
worldwide because of “the lack of consensus regarding which health parameters 
should be monitored”9. Studies done in 1986 and 2004 showed that recording of 
physical examination on admission of psychiatric patients was poor10.  The authors of 
a study in 2005 that examined baseline testing and ongoing monitoring of 
cardiovascular and other risk factors in schizophrenic patients who were on SGAs 
concluded that there was a very low level of baseline and ongoing monitoring of tests 
in these patients11. Also as recently as 2009 an audit on physical examination of 
patients at the time of admission, at North Derbyshire Mental Health Services NHS 
Trust, revealed that only 67% of patients were examined according to the guidelines12.  
The authors of an article that advocates improving physical health monitoring for 
patients on antipsychotic therapy suggest that in addition to regular audits of practice 
and ongoing training of team members especially doctors there should be the 
inclusion of a monitoring tool in the patients’ clinical notes which would act as a 
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prompt13. In keeping with this recommendation the collective evidence from three 
previous QUM studies and a drug utilisation evaluation (DUE) on clozapine done at 
The Park – Centre for Mental Health, where this study is being conducted, also point 
to the need for a decision support tool that would act as a prompt for clinicians 
(pharmacists, prescribers and nurses) caring for patients on clozapine therapy14,15,16.  
Most of the errors in these studies were of a clerical nature; a finding that is in 
keeping with other similar studies on prescribing errors in a psychiatric setting, 
nevertheless the potential for patient harm is ever present17.  
 
Three QUM studies on prescriber related errors and a drug utilisation evaluation 
(DUE) on clozapine which were done at The Park – Centre for Mental Health (The 
Park), where this study is being conducted, revealed that the interventions between 
studies had a positive impact on error rates with each subsequent study showing a 
decline in the number of errors. The interventions between studies concentrated on 
increasing clinician awareness of errors and education on prescription writing 
techniques and adherence to the monitoring requirements associated with clozapine 
therapy. The positive impact of this was short-lived because this tacit knowledge was 
lost when staff relocated to other wards and facilities. This highlighted the need for a 
decision support tool that could act as a quick reference guide and be available at all 
times for clinicians (pharmacists, prescribers and nurses) caring for patients on 
clozapine therapy.   This is in keeping with the recommendation above by Gonzalez et 
al13. 
 
The rationale for the development of guidelines in clinical settings is to improve the 
quality of care that a patient receives with the aim of improving the health outcomes 
and hence the quality of life (QOL) of the patient18,19. There is growing acceptance 
internationally, of the importance of using standardised guidelines or pathways as a 
decision support tool in clinical practice; but for these to be of any benefit they must 
be simple, user friendly and patient specific20,21,22. 
 
Guidelines were first introduced as a tool for prescribers, aimed at minimising the 
emergence of resistant organisms23. The Therapeutic Guidelines Limited (TGL) has 
produced a set of guidelines, for use by health practitioners that are practical, clear 
and easy to use for the management of patients with specific conditions. These 
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guidelines cover all common disorders encountered in clinical practice and contain 
information that is unbiased, independent and current evidence based.  
 
In order to raise the standard of individual and public health in Australia, the National 
Health and Medical Research Council (NHMRC) promotes the development of 
evidence based guidelines24. However there are significantly opposing views on the 
subject of guideline development and implementation. On the one hand there is the 
view that guidelines are essential to all areas of clinical practice and on the other hand 
they are often viewed as being too restrictive by preventing the clinician from making 
independent clinical decisions based on prevailing circumstances18. The NHMRC sets 
standards and procedures for externally developed guidelines which are evidence 
based statements that guide practitioner decision making in specific clinical settings25. 
In addition guidelines are seen as a means of providing a framework that lends itself 
to quality assurance, audit checks, research and evaluation of level and type of care 
being offered26,27. 
  
1.2 Schizophrenia 
Schizophrenia can be defined as “a mental disorder characterized by a breakdown of 
thought processes and of emotional responsiveness”28. The common manifestations of 
schizophrenia are paranoid delusions, auditory hallucinations or disorganized 
thoughts and speech which usually results in occupational and social dysfunction29.   
 
Aetiology 
There is no single cause of schizophrenia and this is supported by the fact that a 
common cause could not be identified in all patients diagnosed with the condition. 
The currently held view that schizophrenia is a combination of life events as well as 
“brain vulnerabilities (either inherited or acquired)” is based on the widely known 
‘stress-vulnerability’ model which was proposed by Zubin et al about 35 years ago 30. 
The early manifestations of the condition usually occur during late adolescence or 
early adulthood when the diagnosis is usually first made, which suggests that there 
may be a link to the changes occurring towards the end of adolescence31. According 
to current evidence onset is earlier in males than it is in females and while oestrogen 
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has been postulated to play a part in the development of the condition, socio-cultural 
influences has also been hypothesised as being the cause31. 
 
The following have been implicated in the development of schizophrenia: 
Genetic predisposition  
There is a 6.5% risk of developing schizophrenia if one has a first-degree 
relative with the disease and amongst monozygotic twins with the disease 
more than 40% are affected32.  
 
 Environmental factors 
Exposure to urban living as a child or adult increases the risk of developing 
schizophrenia even after controlling for factors such as ethnicity and substance 
abuse32,33.  A study in Sweden showed that for people living in an urban 
environment the risk of being diagnosed with a psychosis increased by about 
72% 34.   
 
Adverse Social factors 
Children growing up in low a socioeconomic environment and those who have 
suffered social exclusion are at greater risk of developing schizophrenia than 
children from higher socioeconomic backgrounds35. There is also a 
considerable risk of developing schizophrenia with either personal or recent 
family history of migration associated with racial discrimination, social defeat, 
unemployment and poor living conditions36.   
 
Substance Abuse 
In a recent study the rate of substance use within the schizophrenic population 
was found to be about 60% of which 37% were regarded as having a substance 
use disorder37. It has also been argued that drug use is as a result of patients’ 
wanting to overcome the negative symptoms of schizophrenia or those 
negative feelings related to prescription drugs being used for the treatment of 
schizophrenia. There is currently a lack of sufficient evidence to associate 
drug use in general, with schizophrenia. There is however strong evidence that 
links certain drugs to either initiating schizophrenia or causing a relapse of the 
condition in susceptible individuals37. Regular cannabis use can double the 
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risk of developing schizophrenia and may be responsible for as much as 8% of 
all those diagnosed as having schizophrenia38. Amphetamine use causes the 
release of dopamine which leads to a potentiation of the effects of this 
neurotransmitter which according to the dopamine theory is responsible for the 
symptoms of schizophrenia and in patients with schizophrenia it may worsen 
the symptoms39. The hallucinogens ketamine, phencyclidine (PCP) and 
lysergic acid diethylamide (LSD) can all produce schizophrenic states and 
have been used in the past for research purposes.    
 
Prenatal 
Prenatal risk factors such as prenatal infection, intrauterine malnutrition and 
prenatal stress may result in an increased risk of developing schizophrenia 
later in life29. Foetal hypoxia is another risk factor which results in a 
hippocampus with a reduced volume which in turn is associated with 
schizophrenia40.  
 
Epidemiology 
The old view that schizophrenia was a disease of the lower social classes was 
dispelled by Goldberg and Morrison in 1963 who showed that there was no difference 
between the social class distribution of the fathers of schizophrenic patients, at the 
time of birth of these patients, and the population in general41,42,43. Despite other 
studies in this area the evidence is currently lacking to reach a conclusion on this 
matter44,45. The latest statistics according to the World Health Organisation is that 
about 24 million people worldwide are currently diagnosed as having schizophrenia46. 
It is more common in males (about 1.4 times more) than it is in females and the onset 
is earlier in males (between the ages 20 to 28 years) as compared to females (26 to 32 
years) 32,47. Onset outside these age ranges are rare48,49.  
 
Pathophysiology  
Ever since the discovery of the usefulness of chlorpromazine in patients with 
psychotic symptoms, by Henri Laborit in 1950, dopamine has been implicated in the 
pathophysiology of schizophrenia50. This led to the so called dopamine hypothesis of 
schizophrenia which is based upon the observation that in general, antipsychotics are 
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dopamine receptor antagonists to some degree. All antipsychotics, typical and 
atypical, have been found to be antagonists at the dopamine D2 receptor to some 
extent; even those antipsychotics classed as partial agonists51. This rather simplistic 
view has evolved with time and based on current evidence it is now thought that 
schizophrenia is associated with excessive stimulation of dopamine D2 receptors in 
the nigrostriatal pathway, poor stimulation of dopamine D1 receptors in the prefrontal 
cortex and a reduction in ‘glutamate (GLU) transmission at N-methyl-D-aspartate 
(NMDA) receptors’ in the prefrontal cortex52.  The evidence supporting this current 
view lies in strong pharmacological evidence which in turn is supported by brain 
imaging studies52.  
 
Diagnosis 
The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and 
International Classification of Disease (ICD-10) are two systems currently available 
to psychiatrists worldwide, which stipulate the conditions that have to be met for the 
diagnosis of schizophrenia53,54. According to DSM-IV text revision (DSM-IV-TR) the 
following are required for a diagnosis55: 
 
 Two or more of the following symptoms (delusions, hallucinations, disorganized 
speech, disorganized behaviour, negative symptoms) for one month 
and 
 A six month period of signs of illness with impaired self-care, occupational or 
social behaviours with at least one month of active symptoms. 
 
 The diagnosis of schizophrenia is complicated and requires the psychiatrist to 
identify a large number of observed behavioural symptoms which reflect disorders of 
perception and cognition whilst at the same time recognising other medical conditions 
that could give rise to similar behaviour patterns56. In addition the patient’s reported 
experiences are also taken into account. Due to the complex nature of the condition as 
well as the difficulties associated with the diagnosis of schizophrenia a cautious 
approach is usually adopted at the time of initial diagnosis and the term 
schizophreniform is used if symptoms exist for ≥ one month57. If at the end of a six 
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month period there is no improvement in symptoms the diagnosis must be changed to 
schizophrenia hence schizophreniform as a diagnosis cannot be used beyond a six 
month period57. 
 
Treatment  
Current treatment of schizophrenia largely depends upon the control of symptoms 
with medication58. The response is fast and complete if medication is initiated soon 
after symptom onset57.  The drugs used in the treatment of schizophrenia are classed 
as first generation (FGA) or conventional antipsychotics and second generation 
(SGA) or atypical antipsychotics based on receptor affinity57). The response to drug 
treatment varies and not all patients respond appropriately. Those who do not respond 
favourably even after trialling two different antipsychotics are classed as having 
‘treatment resistant schizophrenia’. In addition electroconvulsive therapy (ECT) is 
also used in instances where drug therapy alone does not offer control of the 
symptoms. The effectiveness of these interventions are measured using tools such as 
the Clinical Global Impression Improvement scale (CGI-I), Positive and Negative 
Syndrome Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS) 59,60.  
 
Conventional antipsychotics have been used since the early 1950s with the discovery 
of the therapeutic potential of chlorpromazine as a neuroleptic61. It is a phenothiazine 
derivative and is widely accepted as being representative of this class of 
antipsychotics and is still used as a reference against which the potencies of all other 
conventional antipsychotics are measured61,62.  
 
Second generation antipsychotics are said to cause fewer extra-pyramidal side effects 
(EPSEs) than the first generation antipsychotics and some even have the advantage of 
not affecting prolactin levels62. The SGAs, with the exception of clozapine, have not 
been shown to be much more efficacious than the FGAs62. However because of its 
side effect profile, treatment with clozapine requires monitoring of baseline 
parameters before initiation of drug treatment, mandatory haematological monitoring 
at initiation and during maintenance phases of treatment as well as ongoing physical 
health monitoring. Clozapine is reserved for treatment resistant schizophrenia and is 
licensed for this purpose in Australia63. 
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1.3  Treatment Resistant Schizophrenia 
It can be argued that all patients with schizophrenia are treatment resistant because of 
the lack of full remission in those people who have been diagnosed as having this 
condition even those on clozapine therapy64. Hence it is necessary to define the term 
treatment resistant schizophrenia. In attempting to do this, Kane in 1996 stated that 
the following criteria must be addressed before a diagnosis of treatment resistant 
schizophrenia can be made65 (p10): 
 
 available medications and other treatments are not useful in alleviating the target 
symptoms of schizophrenia (not only the positive and negative symptoms, but also 
disorganised or violent/aggressive behaviour, thought disorder and suicidal ideation) 
 occurrence of adverse side-effects of medication 
 non-adherence to current treatment 
 presence of co-morbid conditions such as substance misuse 
 failure of maintenance and relapse despite seemingly adequate doses of antipsychotics  
 
Furthermore failure to respond to at least two anti-psychotic drugs with a 
chlorpromazine equivalent of 600 mg daily for more than four weeks in addition to 
the above is regarded as treatment resistant66. The drugs that have been used 
successfully in partially treatment resistant schizophrenia are risperidone and 
olanzapine but in more severe cases of treatment resistance, clozapine is undoubtedly 
more superior in controlling the symptoms of schizophrenia64. The National Institute 
for Clinical Excellence (NICE) schizophrenia guidelines actually advocate broader 
and earlier use of clozapine which suggests that there should be a trial of only one 
atypical before progressing to clozapine64,67. Patients who prove resistant to adequate 
doses of clozapine over a sufficient period of time may benefit from switching to a 
previously untried SGA such as risperidone, quetiapine or olanzapine64. If this fails a 
trial of clozapine augmentation with lamotrigine, amisulpride or strong inhibitors of 
the hepatic isoenzyme CYP1A2 such as fluvoxamine, which has the net effect of 
increasing the plasma concentration of clozapine, may offer some success but there is 
as yet no general consensus as to which drug regime would suit which patient63, 64. 
Nevertheless the augmentation strategy can give rise to polypharmacy, something that 
is strongly discouraged by current schizophrenia guidelines, except if it is clinically 
justified62.  
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1.4 Adherence 
“Drugs don’t work in patients who don’t take them”68 
— C. Everett Koop, M.D  
Patient adherence to drug treatment  
The term that best describes the extent to which a patient takes his or her medications 
as prescribed by their clinician is adherence, because it implies that there is the 
existence of a therapeutic alliance between the patient and the clinician69. 
Studies on adherence to medication within the schizophrenic population show that the 
problem of non-adherence is widespread and that there is a general decline in 
adherence to medication with the passage of time after discharge from hospital70,71,72.  
Only about a quarter of the patient population have been found to be adherent with 
their medication with 50 to 75 percent relapsing within a year because of non-
adherence70,73,74,75. The treatment of schizophrenia is heavily dependent upon 
pharmacotherapy76. Hence adherence to antipsychotic drug treatment by patients is 
extremely important since non-adherence could lead to a fourfold increase in the risk 
of suicide attempts70. On the other hand a lack of symptom improvement or 
worsening symptoms could give the clinician the false perception of treatment failure 
and an incorrect diagnosis of treatment resistance. Therefore adherence to drug 
treatment must be thoroughly investigated to rule out any form of non-adherence 
before progressing onto treatment with clozapine. In addition before commencing a 
patient on clozapine therapy the Multidisciplinary Team (MDT) is guided by a few 
basic principles including but not limited to an assessment of co-morbidities and a re-
evaluation of the diagnosis in light of the possibility of an organic cause77.  
 
The authors of a recent retrospective study concluded that patients who are on SGAs 
(atypical antipsychotics) are more likely to be adherent to treatment than if they were 
on FGAs (typical antipsychotics) 78. Adherence was measured by “adherence intensity 
(how well a patient follows physician instructions during the course of treatment with 
an antipsychotic) and persistence with therapy (how long a patient stays on 
treatment)” 78. A possible explanation for this according to the authors is that the 
observed improved adherence associated with SGAs is due to the fact that, as 
mentioned in the literature, SGAs are better than FGAs in improving negative 
symptoms and cognition79,80. Another reason given for non-adherence to drug 
treatment amongst people with schizophrenia is that quite frequently there is a lack of 
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awareness of mental illness81. Another study on this subject shows no difference in 
non adherence rates between FGAs and SGAs82.  And other previous studies yield 
mixed results regarding adherence rates to FGAs compared to SGAs83,84.  
  
A recent study concluded that although the use of SGAs have grown and that their use 
is now widespread there is still a great deal of underuse and over filling of 
antipsychotic prescriptions by patients with schizophrenia82. The diverse nature of the 
reasons for non adherence has led to a suggestion by the authors of studies in this field 
that interventions on multiple levels are required to combat non adherence to drug 
treatment82,83. In a study of the predictors of risk of non-adherence it was found that 
adherence to medication among patients who were on clozapine was considerably 
longer than those who were on other antipsychotics85. This increased adherence to 
medication has been attributed to the reduction of symptoms by clozapine and the 
concurrent improvement of cognition which increases insight into the importance of 
medication compliance86. It is also possible that the observed benefits of clozapine are 
due to its lack of extra-pyramidal side effects (EPSEs) in conjunction with the 
above87. Yet another explanation is that the close monitoring requirements together 
with frequent clinical contact and regular blood tests associated with clozapine 
therapy encourages adherence. There may also be the mistaken belief by patients that 
the regular Full Blood Count (FBC) checks are a check for drug levels in the blood. 
Also there is the possibility that before patients are selected for clozapine therapy they 
are “informally preselected for adherence” because patient compliance with 
medication regimes and monitoring requirements are essential for clozapine therapy85. 
 
The prescriber’s choice of drug is also important because drugs with poor tolerability 
can lead to non-adherence by the patient, because of increasing side effects88. The 
consequences of non adherence to antipsychotic drug treatment can be serious.  Non 
adherent patients are at greater risk of exacerbation of the symptoms of schizophrenia 
compared to those who are adherent to medication89. It has also been shown that the 
non adherent patient is at increased risk of housing instability, hospitalization at a 
mental health facility and violence90,91,92. Those patients who lack the insight or 
awareness of having a mental illness are at increased risk of non-adherence and 
hospitalization93. There is a general tendency for non-adherence to antipsychotic 
medication in these patients to be prolonged with clinically disruptive consequences81. 
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Psychological approaches such as Cognitive Behaviour Therapy (CBT) have been 
tried to improve adherence but with limited success. The greatest benefit to patients 
by way of adherence to medication was observed with psycho-education of family 
members, observing the patient taking medication on a daily basis and switching from 
oral dosage forms to depot medication81.  And then there is the perception by some 
patients that antipsychotic medications do not prevent relapse and that they will never 
be re-hospitalized these perceptions being brought on by the effects of non-adherence 
to antipsychotic medications94.  
 
In summary, current evidence on adherence to antipsychotic drug treatment by 
schizophrenic patients’ points to better adherence by those patients on clozapine, for 
the reasons mentioned above, as compared to those patients taking other antipsychotic 
medications85,86,87.   
 
Clinician adherence to guidelines 
The essential differences between antipsychotic drugs lie in their tolerability and 
safety95. All international guidelines on the management of schizophrenia suggest 
treatment strategies designed to improve tolerability and minimise side effects thereby 
ensuring greater safety96,97,98,99.  
 
There is very little by way of published reports of studies on adherence or non-
adherence to antipsychotic guidelines by health care workers in a mental health 
setting indicating that very little research has been carried out in this area. Of the little 
that appears in the literature there is an emphasis on whether dosing guidelines are 
being followed or breached. Nevertheless not much appears to be known about the 
factors affecting the dosing of a patient according to current treatment guidelines and 
recommendations76. In an attempt to look at what factors play a part in affecting 
dosing of antipsychotics, a retrospective study was conducted by looking at 
antipsychotic prescriptions dispensed over a one week period to a group of patients 
diagnosed with schizophrenia76. The study revealed that female patients were less 
likely to be dosed within the guideline recommendations with their doses usually 
below the recommended range. The doses of black patients were usually within the 
guidelines but when outside the range these were usually above the recommended 
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maximum dose76. Patients with co-morbid medical conditions were less likely to be 
dosed within the recommended range and were usually below the recommended 
range76. The investigators hypothesised, that doses of antipsychotics prescribed by 
mental health specialists for patients treated at specialist mental health facilities, 
where there was an emphasis on education and research, would be within current 
guidelines76. The assumption being that mental health specialists working in a mental 
health facility would be more aware of the dosing guidelines and recommendations 
than non-mental health physicians and were therefore more likely to dose according to 
the guideline recommendations76. Interestingly the results showed that patients in this 
setting were more likely to be dosed above the guideline recommendations76. 
 
The phenomenon of antipsychotic polypharmacy for extended periods among 
schizophrenia patients is prevalent and is on the increase100. Current guidelines do not 
advocate antipsychotic polypharmacy, because of the associated side effects, except 
for short periods when cross-titrating during changeover to another antipsychotic100. 
In the case of treatment resistant schizophrenia the current view is that SGAs are 
generally more effective than FGAs and that successful control of symptoms usually 
requires augmentation with other medication101.  
 
An important aspect of adherence to guidelines is the acceptance of the guidelines by 
both the patient and the prescriber102. Psychiatrists often appear to be non-adherent to 
treatment guidelines that they themselves are in agreement with or have previously 
endorsed. This is because of the patient’s refusal to have their medication changed in 
accordance with treatment guidelines102. Also, non-compliance on the part of the 
patient forces the psychiatrist to prescribe outside the guideline recommendations102. 
It has been difficult to implement a standardised set of treatment guidelines in clinical 
practice because of the great differences in prescribing patterns of antipsychotics 
around the world103, 104. Studies have shown that patients who have a history of 
previous inpatient treatment, co-morbid conditions and those with a high degree of 
recidivism are more likely to receive drug regimes that are outside guideline 
recommendations105. Current antipsychotic treatment guidelines advocate the use of 
SGAs as first line in the treatment of schizophrenia and mono-therapy as the preferred 
method of drug treatment. 
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While the implementation of antipsychotic treatment guidelines has been an arduous 
task and we know that treatment guidelines are frequently not followed, it must be 
remembered that their usefulness in the areas of tolerability and safety cannot be 
overemphasized102. Without guidelines patients are at greater risk of being prescribed 
drugs with poor tolerability and/or safety and may experience side effects which 
would lead to non-adherence to drug treatment. The consequences of non-adherence 
to antipsychotic medication treatment guidelines also increase the risk of relapse and 
the severity of relapse as well as rehospitalisation and the duration of 
rehospitalisation70,95. Other consequences are increased health care costs and an 
increased burden on the health care system as well as increased suffering of patients 
and those close to the patient85.  
 
1.5 Overview  
Schizophrenia is a complex condition to diagnose and treat. An initial diagnosis of 
schizophreniform is usually made in the presence of symptoms persisting for ≥ 1 
month and changed to schizophrenia if symptoms persist for > 6 months57. 
Pharmacotherapy is the mainstay of treatment for schizophrenia with the available 
drugs being classed as either FGAs or SGAs57. Current literature supports the use of 
SGAs as first line treatment and also advocates monotherapy, to minimise side 
effects, when using antipsychotics in the treatment of schizophrenia106. A large 
portion of the schizophrenic population are said to be treatment resistant as defined 
above and require treatment with clozapine which is reserved and licensed for this 
purpose63.  Within this group there are those who do not respond to clozapine alone 
and require augmentation with other drugs to achieve symptom control. The evidence 
supporting augmentation is weak and the results of augmentation in practice are 
usually disappointing62. If the response to augmentation is poor these patients are 
classed as being clozapine resistant and may require ECT, psychotherapy and social 
support in addition to a combination of other antipsychotic drugs. Non-adherence on 
the part of patients to drug treatment and/or non-adherence on the part of clinicians to 
antipsychotic guidelines can also create a false notion of treatment failure which in 
the case of clozapine has serious implications for the patient. The latter being the 
driving force behind this study.     
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2 AIMS 
 
The aims of this research are: 
 
2.1 To develop a Clozapine Decision Support Tool (CDST), which would be 
in the form of a quick reference guide that outlines: 
 the steps to be followed when initiating a patient on clozapine  
 the baseline monitoring that must be performed before initiation of 
treatment 
 starting dose and up-titration schedule  
 target doses based on gender and smoking status of the patient 
 the initial and ongoing mandatory haematological monitoring and 
other physical health monitoring that must be performed  
 what steps the clinician should follow in the event of a break in 
treatment 
 
2.2 To assess whether use of the CDST by clinicians increased their level of 
adherence to current clozapine guidelines by comparing pre- and post-
interventional: 
 completion of blood count forms 
 medication orders for clozapine 
 prescriptions for clozapine 
 monitoring of baseline parameters before commencing clozapine 
therapy 
 intense physical health monitoring at initiation 
 haematological, cardiovascular, metabolic and physical health 
monitoring during the up-titration as well as the maintenance phases 
of treatment 
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3 METHOD 
 
3.1  Study 1 – Development of the CDST 
Introduction 
Patient safety and the promotion of quality care improvements were the main drivers 
behind the development of the CDST. The three QUM studies and the DUE discussed 
earlier showed that the number of errors associated with the act of prescribing the 
antipsychotic clozapine, fell substantially each time an intervention was introduced14, 
15,16
. The interventions mainly focused on increasing clinician (prescriber, nurse and 
pharmacist) awareness of the guideline recommendations on the prescribing, 
dispensing and administration of clozapine including the latest evidence based 
monitoring requirements. These interventions usually consisted of in-house, education 
and training sessions with the clinicians. The evidence from the DUE on clozapine 
that was carried out, after the three QUM studies mentioned above, show that the 
interventions had a positive impact on the reduction of the number and frequency of 
errors associated with clozapine prescribing107. It must be remembered that the 
interventions were for the most part verbal in nature. With the passage of time there 
was a gradual erosion of this tacit knowledge because of the movement of staff who 
possessed this knowledge to other wards or facilities. Consequently the number of 
errors associated with clozapine prescribing began to rise once again. It was this 
occurrence that prompted the idea of developing a tangible decision support tool that 
would be easily accessible to all staff at all times when dealing with patients who are 
on clozapine therapy. 
 
The QUM studies identified the prevalence of variation in the act of prescribing 
clozapine among practitioners at The Park. An appropriate response to such a 
situation according to the NHMRC is to develop a set of evidence based guidelines to 
act as a link between the best available evidence and good clinical practice24. The 
main aim of this is to attain better health outcomes for the consumers by improving 
the practice of health care professionals. 
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Procedure 
During the creation of the CDST the guiding principles underlying guideline 
development were followed to impart strength and validity to the recommendations 
within this decision support tool.     
 
Hence the following basic principles were adhered to in the development process: 
 The CDST should be outcome focussed. 
 The recommendations within the CDST should be based on the best available 
evidence. 
 Multidisciplinary consultation and approval of the CDST was regarded as 
mandatory.  
 Promotion of the quality use of medicines (QUM) by focussing on minimising 
errors associated with the prescribing, dispensing and administration of 
clozapine.  
 Inclusion of current evidence based monitoring requirements associated with 
the initiation, up-titration and maintenance phases of clozapine therapy in the 
CDST. 
 The development of the CDST should take into account any prevailing 
resourcing constraints. 
 The CDST should be flexible and adaptable to suit local conditions. 
 
The CDST is made up of two components: a Clozapine Quick Reference Guide 
(CQRG see Appendix A_1) and a Clozapine Initiation Pathway (CIP see Appendix 
A_2).  
 
Clozapine Quick Reference Guide 
The CQRG is a collection of essential information required for the prescribing, 
dispensing and administration of clozapine as well as the monitoring of patients who 
are on clozapine therapy. This information has been presented in the form of tables 
and short sentences aimed at giving the clinician clear and easy to read directions. It is 
important to make the clinician’s first experience, with any new guide or prescribing 
system, one that would encourage acceptance and adoption of the new system rather 
than resistance108. The CQRG contains information on matters such as up-titrating a 
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patient’s dose and monitoring requirements based on current available evidence as 
well as the steps to be taken in the event of therapy interruption. In this way the 
CQRG acts as a true clinical decision support tool in that it links knowledge to 
clinical events. Evidence based practice not only has benefits for the medical 
profession but has also been shown to significantly improve the lives of those 
consumers who receive the evidence based services109. All the information contained 
in the CQRG is information that is currently available but in fragmented form in 
different texts and databases. This was an attempt to get all relevant information into 
one document for ease of reference by members of the MDT. 
  
 
The process for initiating a patient on clozapine therapy is set out in three easy to 
follow steps.  
 
The first step is to notify the clozapine co-ordinator that the MDT has decided to 
commence a patient on clozapine therapy. In keeping with current protocols the 
clozapine co-ordinator is required to register all new patients with a clozapine 
monitoring centre depending on which brand of clozapine is going to be used110,111. In 
the event that a patient’s brand of clozapine is changed then the clozapine co-
ordinator is required to notify the relevant monitoring centres of this change; and the 
monitoring of the patient is then transferred to that centre associated with the new 
brand of clozapine. When the patient registration is complete the co-ordinator informs 
the MDT of the patient’s clozapine number. 
 
The next step is the completion of the following baseline measurements by a 
designated member of the MDT usually a Clinical Nurse (CN) or Clinical Nurse 
Consultant (CNC): 
 
 
FBC (WCC & NC) 
Measuring the white cell count (WCC) and neutrophil count (NC) before 
commencing clozapine is absolutely essential and mandatory since 95% cases 
of agranulocytosis occurs during the first six months of treatment with weeks 
4 to 18 being the period of highest risk112. 
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ECG and ECHO 
The association of potentially fatal myocarditis and cardiomyopathy with 
clozapine therapy has led to the inclusion in current guidelines of baseline 
recordings of ECG and ECHO as a requirement before patients commence 
treatment with clozapine110,111. These pre-treatment recordings are useful for 
future comparisons if symptoms of myocarditis and cardiomyopathy develop 
later.    
 
CK and Troponin levels 
Creatine Kinase (CK) and more specifically Troponin I (TnI) are assayed in 
blood tests as markers of injury to the myocardium113. Baseline levels are 
therefore useful for future comparisons if symptoms develop later. 
 
Fasting Glucose, Fasting Lipids, Weight, Height and Waist Circumference 
The newer antipsychotics and in particular clozapine has been associated with 
elevated blood glucose and triglyceride levels as well as weight gain114. Pre-
treatment blood glucose and lipid levels will assist clinicians in future 
comparisons if necessary and weight and height are used to calculate the 
patient’s body mass index (BMI) at initiation.  
   
Urea and Electrolytes (U&E) 
Baseline U&E facilitates assessment of renal function as clozapine is 
contraindicated in severe renal impairment63. In addition a baseline U&E 
including assays for calcium (Ca++) and magnesium (Mg++) are useful 
especially because of the close association of these ions with arrhythmias and 
the propensity of clozapine to cause tachycardia as a common side effect.  
 
Bowel Habits 
The establishment of patients’ bowel habits at initiation is important firstly 
because clozapine is contraindicated in the presence of paralytic ileus and 
secondly because constipation is a common side effect of clozapine therapy63. 
Baseline bowel habits will have a bearing on the selection of future strategies 
if symptoms of constipation develop after initiation of clozapine therapy.  
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Blood Group 
The patient’s blood group is required as an identifier at the time of registration 
with a clozapine monitoring centre 110,111 . 
 
Mental State 
An assessment of the patient’s mental state is made with due consideration 
being given to the influence of current medications115.  
  
The selection of these baseline requirements was influenced by current evidence and 
current best practice62,110,111. If all baseline requirements are within acceptable limits 
the prescriber is informed and treatment with clozapine may commence. 
 
The final step of this initiation phase is the act of prescribing clozapine by a 
psychiatrist or psychiatry registrar provided that the blood sample upon which the 
above baseline measurements were performed is not greater than ten days old. All 
relevant documentation must be completed by the prescriber and sent to the pharmacy 
department for dispensing.  Prescribers are encouraged to perform this task on their 
own as studies have shown that assistance in the completion of documentation by 
persons other than the prescriber increases the risk of error16.  
 
The prescriber is guided by a dosing schedule which sets out the times and doses for 
the first 28 days. The first dose of 12.5 mg is to be given on the morning of the first 
day with gradual increments from day two onwards until the desired target dose is 
reached62. This dosing schedule is to be read in conjunction with the guide, which 
appears below it, to achieve a target serum level of 350 micrograms/L based on 
smoking status and gender116.  
In this way treatment is directed towards achieving a target dose within a given time-
frame. It must be mentioned that this is only a guide for the prescriber and that serum 
clozapine levels as well as psychological and other clinical assessments will direct 
future treatment goals and strategies. 
 
To assist with the proper monitoring of patients on clozapine therapy is a table which 
sets out the intense monitoring requirements at initiation as well as the weekly, 
  20 
monthly and six monthly monitoring requirements based on current best practice and 
current evidence62. 
 
In addition there are tables which set out the recommencement requirements and 
strategies to be employed and blood test monitoring that must be performed based on 
the length of interruption to therapy110,111.   
 
Also included is a list of clozapine – drug interactions as a quick reference. The 
cytochrome P450 enzyme system is responsible for the metabolism of clozapine in the 
liver. CYP1A2 is recognised as the main hepatic isoenzyme responsible for the 
metabolism of clozapine via demethylation to the major metabolite desmethyl-
clozapine (norclozapine) which is itself pharmacologically active116,117.  Hence drugs 
that induce CYP1A2 will decrease the serum concentration of clozapine which in turn 
can lead to treatment failure and relapse, and those drugs that inhibit CYP1A2 will 
cause an increase in serum clozapine levels and increase the risk of serious side 
effects such as agranulocytosis or cardiomyopathy63. These serious side effects could 
be falsely attributed to adverse drug events caused directly by clozapine. Cessation of 
clozapine on this basis could lead to treatment failure or relapse which may require 
hospitalization, at great cost to the health care system as well as increased suffering to 
the patient and patient’s family. This would inappropriately but effectively remove 
clozapine as a choice in a patient with treatment resistant schizophrenia and raises 
new challenges for the MDT whose goal it is to obtain symptom control in that 
patient. Cigarette smoking can decrease serum clozapine levels by up to 70% due to 
induction of CYP1A2 by the poly-cyclic aromatic hydrocarbons in cigarette 
smoke116,118.  This could lead to treatment failure and relapse and may require 
hospitalization119.  However if a patient who is on a stable dose of clozapine, stops 
smoking, there could be a dramatic rise in serum clozapine levels which could lead to 
toxicity and serious unwanted side effects also requiring hospitalization119.  Caffeine 
consumption on the other hand increases serum clozapine levels because caffeine acts 
a substrate for CYP1A2120.  It is because of the serious consequences of these 
interactions with clozapine it was decided to include a table listing some of the more 
important drug interactions. 
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To assist prescribers in making informed decisions about dosage adjustments, a 
formula was included that aids in the prediction of serum clozapine levels based on 
smoking status121. This formula states that the non-smoking serum clozapine level in 
nanograms/mL can be calculated by multiplying the smoking clozapine level in 
nanograms/mL by a factor of 1.474 and adding the result to 45.3118.  
 
 
Clozapine Initiation Pathway 
The CIP was included in the CDST as part of ongoing quality improvement (QI).  
This pathway is aimed at improving the performance of medical, nursing and 
pharmacy staff and is presented as a flow chart because it has been shown that 
flowcharts are beneficial when used as a means of managing various processes in 
many fields122. In this instance it is a graphical representation of the step by step 
process involved in the initiation, up-titration and maintenance of clozapine therapy 
with the aid of colour coded, annotated geometric shapes connected by flow lines. 
The advantages of a flow chart is that it promotes an understanding of the processes 
involved, provides a way of training staff and identifies problem areas and 
opportunities for process improvement. The CIP is made up of three sections that are 
colour coded as follows: 
     
The Green Section 
The green section is a series of steps that occur without hindrance from the time the 
MDT decides to start a patient on clozapine therapy. This begins with the taking of 
the blood sample and registration of the patient with the clozapine monitoring centre, 
the subsequent baseline measurement and recording, the commencement of the first 
dose then weekly review for 18 weeks and finally the progress onto a monthly review 
cycle provided that the white cell count (WCC) > 3.5 x 109/L and Neutrophil Count 
(NC) > 2.0 x 109/L at each review110,111.  
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The Amber Section 
When the FBC yields a WCC of 3.0 – 3.5 x 109/L and/or a NC of 1.5 – 2.0 x 109/L the 
pathway changes to amber thereby signifying caution110,111. If the blood result is in the 
amber range before initiation, treatment with clozapine cannot commence until a 
subsequent blood test yields a green result. The guidelines suggest repeating the FBC 
in 7 days110,111. If an amber result is encountered during treatment with clozapine the 
guidelines suggest twice weekly monitoring of FBC until a green result is obtained 
after which normal regular monitoring either weekly or monthly should continue 
depending on whether the patient is in the 18 week up-titration phase or the stable 
monthly monitoring phase respectively110,111. 
 
The Red Section 
If the FBC yields a WCC < 3.0 x 109/L and/or a NC < 1.5 x 109/L the pathway 
changes to red thereby signifying extreme caution110,111. If the blood result is in the 
red range before initiation, treatment with clozapine cannot commence and the team is 
directed to seek advice from a haematologist if they wish to continue with clozapine 
treatment for this patient110,111. If a red result is encountered during treatment with 
clozapine the guidelines suggest ceasing treatment and haematologist intervention is 
necessary if there is a desire to continue treatment with clozapine in this patient110,111.  
 
Finally a table on side effects associated with clozapine therapy was included because 
proper management of these side effects facilitates the maximization of benefits for 
the patient123. The table lists some of the more common and important side effects of 
clozapine therapy, the time course of those side effects and also suggest what actions 
the clinician should take when these side effects are encountered62. Some 
interventions like sedation are self-limiting and require little or no intervention while 
other more serious side effects such as myocarditis and cardiomyopathy may require 
ceasing clozapine altogether62. 
 
Ongoing review of the literature on matters related to clozapine is encouraged so that 
best practice and the latest evidence based monitoring requirements are incorporated 
in the CDST. The evaluation of the CDST for usefulness as a decision support tool is 
  23 
the subject of this cohort study where it is being used as the intervention. In addition 
and as a form of continuing quality assurance it will be subjected to annual review, 
evaluation and revision by the Drugs and Therapeutics Committee based at The Park 
– Centre for Mental Health.  While annual review is preferred the maximum 
allowable time between reviews is three years24. The review should focus on 
relevance, appropriateness and whether the information contained within the CDST is 
up to date and in keeping with current best practice.    
 
Dissemination of a newly developed guideline is an essential part of guideline 
development but does not ensure uptake by the target audience. In support of this, 
studies on guideline evaluations have shown that unsolicited mailing of guidelines 
and printed material increases awareness of guidelines but do not change clinicians’ 
behaviour or health outcomes124,125. Studies have also shown that the simple 
dissemination of guidelines generally has no impact on the implementation of the 
same guidelines125,126.  
 
“Guidelines do not implement themselves”127 (p134); hence effective strategies must be 
put in place for their dissemination and implementation24. If this is not done the time, 
cost and energy that went into developing the guidelines as well as the potential 
improvements in consumer health will be lost. Change can be encouraged by the 
introduction of specific interventions specially designed for this purpose because no 
single implementation strategy is effective in all instances. When designing 
interventions it must be remembered that those interventions most likely to succeed 
are those that require the participation of the clinician in the change process126.  
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3.2  Study 2 – Evaluation of the CDST  
Design 
 
This cohort study assessed the effectiveness of the CDST, which was the intervention, 
in improving clinician adherence to current clozapine prescribing and monitoring 
guidelines.  
 
Participants  
The study population comprised all patients residing at The Park – Centre for Mental 
Health, who were on clozapine therapy during June 2010 and May 2011. There were 
67 patients in the pre-interventional audit and 66 in the post-interventional audit. The 
number of females in both audits was constant at 16 resulting in a very similar gender 
ratio in both audits. The pre and post-interventional mean age (±SD) was 37.6(±8.7) 
years and 37.9 (±9.2) years respectively and the mean weight (±SD) was 93.0(±21.7) 
kg and 97.3(±22.7) kg respectively. 
 
Inclusion criteria: 
 Patients had to have a current diagnosis of treatment resistant schizophrenia. 
 Clozapine had to be part of their antipsychotic drug regime during the study 
period. All patients who were commenced on clozapine therapy during the study 
period were also included in the study. 
 Patients had to be 18 years of age or older. 
Measures   
Clinical Chart and Computer record audit  
This audit gathered information from both the patient’s clinical chart as well as the 
patients’ computer records and was designed to establish whether:  
 the recommended baseline measurements were being conducted and 
recorded by the clinicians prior to commencement of clozapine therapy 
 the recommended observations relating to patient temperature, pulse, 
respiration and blood pressure were performed and recorded during the 
first week of treatment with clozapine 
 the observations were recorded in both the observation charts and the 
patient’s clinical notes 
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 the monitoring requirements during the 18 week initiation phase and the 
maintenance phases of clozapine treatment were being adhered to 
 the recommended cardiac monitoring of baseline and 6 monthly 
electrocardiography (ECG) and echocardiography (ECHO) were being 
conducted 
 
Prescribing Audit 
 
The prescribing audit was conducted during the dispensing process by pharmacy staff 
in the pharmacy department. It was designed to establish whether: 
 all relevant documentation had been submitted by the prescriber to the 
pharmacy department for the dispensing of clozapine 
 the clozapine prescription 
o had a patient identification label 
o was legible 
o conformed to the legal requirements for a prescription 
 the blood count form had been completed by the prescribing medical 
officer in legible handwriting and whether the form had been signed by 
the medical officer 
 the medication chart  
o had a patient identification label 
o was legible 
o had been checked by a clinical pharmacist 
o revealed that doses had been missed 
 the patient identification labels on the prescription and the medication 
chart were for the same patient 
 the blood sample that was used was < 48 hours old and whether the WCC 
and NC  as recorded in the blood count form were transcribed correctly 
from the haematology report. 
The audit also involved recording the dose of clozapine that was prescribed and the 
serum clozapine and norclozapine levels that were assayed from the sample of blood 
used to obtain the FBC.  
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Ethics approval 
This project is a quality improvement initiative aimed at improving the processes 
involved when clozapine is prescribed, dispensed and administered within The Park – 
Centre for Mental Health. Although in-house improvement projects do not generally 
require ethics approval, approval was obtained for this project from the Darling 
Downs West Moreton Health Service District Human Research Ethics Committee in 
the event of any future application for publication. Ethics approval was also obtained 
from The School of Pharmacy, University of Queensland. 
Procedure 
The study was conducted at The Park – Centre for Mental Health in Wacol, 
Queensland. The Park – Centre for Mental Health is a long stay tertiary mental health 
facility with 192 beds and occupancy of approximately 80%.The study was divided 
into 2 data collection periods separated by the introduction of the CDST at the 
beginning of December 2010, referred to as the intervention. Hence the data 
collection periods are referred to as the pre-intervention (June 2010 to November 
2010) and post-intervention (December 2010 to April 2011) data collection periods.  
Pre-intervention phase 
Clinical Chart and Computer record audit  
During June 2010 and November 2010 a six month clinical chart and computer record 
audit was conducted. This data was collected by the principal investigator assisted by 
nursing staff in General Health Services at The Park. A data collection form 
(Appendix B) was used to capture the extent to which current clozapine monitoring 
guidelines were being adhered to. The audit assessed what baseline information had 
been recorded before the initiation of clozapine. It also assessed to what extent the 
nursing staff adhered to the intensive monitoring requirements of the patient during 
the first 6 hours of initiating clozapine treatment. In addition the audit assessed the 
level of haematological monitoring and monitoring of the patients’ physical health as 
well as the level of adherence to the ECG and ECHO requirements during the 18 
week up-titration period and the maintenance phase of treatment. 
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Prescribing Audit  
During November 2010 a one month audit of all clozapine prescriptions handed in to 
the pharmacy for dispensing was conducted. A data collection form was created for 
this purpose (see Appendix C_1 and Appendix C_2). Prior to the commencement of 
this study all pharmacy personnel were instructed on the correct method of 
completion of the form.  This audit assessed the level of adherence of the prescribing 
doctor to current clozapine prescribing guidelines and to the requirement of the 
completion of a blood count form. The level of adherence to a local policy which 
requires the attachment of a copy of the haematology report to the prescription was 
also measured. In addition errors and omissions associated with the clozapine 
prescription, blood count form and patient’s medication chart were also recorded. 
 
The Intervention  
The intervention consisted of the introduction of the CDST, which comprised of the 
CQRG and the CIP, in all clinical areas at the beginning of December 2010. With the 
knowledge of the importance of effective dissemination and implementation of 
guidelines as discussed earlier, the following strategies were adopted to disseminate 
and implement the newly developed decision support tool: 
 Advance notice by way of a Memo to all clinicians at The Park of the planned 
date of introduction. 
 In-house information and training sessions across The Park for prescribers, 
nurses and pharmacists to create an awareness of the existence of this tool as 
well as the potential benefits of using this tool. 
 Introduction of a prompt as suggested by Gonzalez et al. 2010 by way of a 
physical health monitoring prompt (Appendix F) which had to be completed 
by a nurse and handed to the pharmacy with every clozapine prescription. If a 
prescription was presented without the physical health monitoring data the 
Clinical Nurse in charge was immediately notified to implement corrective 
action. 
 Distribution of electronic and laminated hard copies in colour of the CDST to 
all clinicians as well as strategic placement of hard copies in all clinical areas. 
The dissemination and implementation methods were designed to maximise the 
distribution and uptake of the CDST by clinicians. 
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Post-intervention phase  
Clinical Chart and Computer record audit  
During December 2010 and April 2011 a five month clinical chart and computer 
record audit was conducted. This data was collected by the principal investigator 
assisted by nursing staff in General Health Services at The Park. A data collection 
form (Appendix D) was used to capture the extent to which current clozapine 
monitoring guidelines were being adhered to. The audit assessed what baseline 
information had been recorded before the initiation of clozapine. It also assessed to 
what extent the nursing staff adhered to the intensive monitoring requirements of the 
patient during the first 6 hours of initiating clozapine treatment. In addition the audit 
assessed the level of haematological monitoring and monitoring of the patients’ 
physical health as well as the level of adherence to the ECG and ECHO requirements 
during the 18 week up-titration period and the maintenance phase of treatment. 
Prescribing Audit  
During April 2011 a one month audit of all clozapine prescriptions handed in to the 
pharmacy for dispensing was conducted.  A data collection form was created for this 
purpose (see Appendix E_1 and Appendix E_2). Prior to the commencement of this 
phase of the study and because of the five month gap since the last audit, all pharmacy 
personnel were once again shown the correct method of completion of the form.  This 
audit assessed the level of adherence of the prescribing doctor to current clozapine 
prescribing guidelines and to the requirement of the completion of a blood count 
form. The level of adherence to a local policy which requires the attachment of a copy 
of the haematology report to the prescription was also measured. In addition errors 
and omissions associated with the clozapine prescription, blood count form and 
patient’s medication chart were also noted. 
3.3 Statistical analysis 
All data were analysed using the statistical program, SPSS (version 15).  Following 
cleaning and checking of the data for errors, descriptive statistics (means and standard 
deviations) were employed to summarise the data for each of the measures, pre- and 
post-intervention. Chi-square tests were then conducted on non-parametric data to 
assess differences in responses pre- and post-intervention. Paired t-tests were used to 
assess differences in continuous data.  
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4 RESULTS 
 
Patient demographics 
 
There were a total of 67 patients in the pre-interventional audit (audit 1) and 66 in the 
post interventional audit (audit 2). The ratio of males to females (56:11 and 55:11) 
was very similar in both audits as was the mean age and weight across both audits. 
The proportion of weekly to monthly patients (4:63 and 4:62) in both audits was very 
similar with 4 weekly patients in each audit (Table 1).   
 
Table 1: Patient Sample Demographics 
 
Category 
 
 
Pre-intervention Audit 
(Audit 1) 
n, (%) 
 
Post-intervention Audit 
(Audit 2) 
n, (%) 
Males  56(83.6%) 55(83.3%) 
Females  11(16.4%) 11(16.7%) 
Mean Age ±SD (years) 37.6±8.7 37.9±9.2 
Mean Weight ±SD (kg) 93.1±21.7 97.3±22.7 
Weekly patient*  4 (5.9%) 4 (6.1%) 
Monthly patient‡  63 (94.1%) 62 (93.9%) 
Total number of patients 67 66 
* = a patient who is in the first 18 weeks of clozapine treatment and requires 
mandatory weekly monitoring of WCC and NC. 
 
‡
 = a patient who has completed the 18 week initiation phase of treatment and is now 
in the monthly phase of mandatory monitoring of WCC and NC.  
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Baseline Monitoring 
During the study 8 patients were commenced on clozapine therapy, 4 during the pre-
intervention phase and 4 during the post-intervention phase. As a chi-square test could 
not be performed on such a small sample size the results have only been reported as a 
percentage. The results in Table 2 show that bowel habits were not being recorded 
before the intervention but that post-intervention there was 100% compliance to this 
monitoring requirement and that the recording of waist circumference and cardiac 
markers (CK and TnI) doubled after the intervention (Table 2).  
 
 
Table 2: Record of baseline measurements as a percentage of patients 
commencing clozapine therapy 
 
Category 
 
 
Pre-intervention Audit 
(Audit 1) (%) 
 
Post-intervention Audit 
(Audit 2) (%) 
Weight 100 100 
Height 100 100 
Bowel Habits 0 100 
ECG 100 100 
ECHO 100 100 
Waist Circumference 75 100 
Blood Group 100 100 
Urea/Electrolytes 100 100 
FBC (WCC & NC) 100 100 
CK level 50 100 
Troponin levels 50 100 
Fasting Lipids 100 100 
Fasting  Glucose 100 100 
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Physical Health Observations at Initiation 
The post-intervention audit results in Table 3 indicate that there was an overall 
improvement in adherence to the physical health monitoring guidelines at the time of 
initiation of clozapine.  
 
Table 3: Physical Observations at Initiation expressed as a percentage 
 
 
Pre-intervention Audit 
(Audit 1) (%) 
 
Post-intervention Audit 
(Audit 2) (%) 
Time Temp Pulse Resp BP Temp  Pulse Resp BP 
0 min 75 75 75 75 75 100 75 100 
15 min 50 50 50 50 100 100 100 100 
30 min 50 50 50 50 75 100 75 100 
45 min 50 50 50 50 75 100 75 100 
60 min 75 75 75 75 75 100 75 100 
90 min 50 50 50 50 75 100 75 100 
2 hr 75 75 75 75 75 100 100 100 
3 hr 50 50 50 50 50 75 50 75 
4 hr 50 50 50 50 50 75 50 75 
5 hr 75 75 75 75 75 75 75 75 
6 hr  75 75 75 75 75 100 75 100 
10 hr 50 50 50 50 100 100 100 100 
14 hr 50 50 50 50 50 50 50 50 
18 hr 50 50 50 50 50 50 50 50 
22 hr 50 50 50 50 50 50 50 50 
28 hr 75 75 75 75 100 100 100 100 
32 hr 25 25 25 25 75 75 75 75 
36 hr 0 0 0 0 75 75 75 75 
40 hr 75 75 75 75 50 50 50 50 
44 hr 0 0 0 0 50 50 50 50 
48 hr 0 0 0 0 50 50 50 50 
Day 3 50 50 50 50 75 75 75 75 
Day 4 75 75 75 75 75 75 75 75 
Day 5 75 75 75 75 75 75 75 75 
Day 6 50 50 50 50 75 75 75 75 
Day 7 50 50 50 50 
 
 
75 75 75 75 
Temp = Temperature  Pulse = Pulse Resp = Respiration BP = Blood Pressure 
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Weekly Monitoring 
Post-intervention audit data show an improvement in physical health monitoring with 
improvements across all categories (Table 4). Weekly WCC and NC were at 100% 
pre-intervention because haematological monitoring is mandatory and remained stable 
at 100% in the post-intervention audit. Bowel habits were not being monitored before 
the intervention but post-interventional data show 100% monitoring. 
Table 4: Adherence to Weekly Monitoring Guidelines for 18 weeks expressed as 
a percentage 
 Pre-intervention Audit 
(Audit 1) (%) 
Post-intervention Audit 
(Audit 2) (%) 
White Cell Count 100 100 
Neutrophil Count 100 100 
Pulse 50 100 
Bowel Habits 0 100 
Weight 75 100 
Blood Pressure 75 100 
Temperature 75 100 
Respiration 75 100 
 
 
Monthly Monitoring 
Data was collected on adherence to the monthly monitoring parameters which are 
currently recommended in the guidelines62, 110, 111. 
 
Evidence for the white cell count and neutrophil count was obtained from the blood 
count form (Appendix G) supplied by the prescriber with every clozapine 
prescription. As the use of clozapine requires mandatory haematological monitoring, 
the pre- and post-interventional audits revealed 100% compliance for this parameter 
(Table 5).  
 
Evidence for adherence by clinicians to the monitoring requirements of the remaining 
monthly parameters, as set out in the CQRG, was obtained from the patient’s clinical 
notes in the pre-intervention audit and from the clinical notes as well as from the 
physical health monitoring prompt (Appendix F) in the post-intervention audit. The 
post-interventional audit results are highly statistically significant (p = 0.0001) 
indicating a substantial increase in clinician adherence to the physical health 
monitoring requirements for all parameters as shown in Table 5 below. Also included 
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in Table 5 is the percentage increase in adherence for each parameter that was 
measured. 
 
   
Table 5: Adherence to Monthly Monitoring Guidelines 
 Pre-intervention 
Audit 
(Audit 1) 
n, (%) 
Post-intervention 
Audit 
(Audit 2) 
n, (%) 
 
Significance‡ 
 
White Cell 
Count 
Yes 
No 
67 (100%) 
0 
66 (100%) 
0 
*  
 
Neutrophil 
Count 
Yes 
No 
67 (100%) 
0 
66 (100%) 
0 
* 
Temperature  Yes 
No 
19 (28.4%) 
48 (71.6%) 
64 (97.0%) 
2 (3%) 
χ
2 
= 66.71 
df = 1 
p < 0.001 
Pulse  Yes 
No 
20 (29.9%) 
47 (70.1%) 
65 (98.5%) 
1 (1.5%) 
χ
2 
= 67.90 
df = 1 
p < 0.001 
Respiration  Yes 
No 
16 (23.9%) 
51 (76.1%) 
61 (92.4%) 
5 (7.6%) 
χ
2 
= 64.08 
df = 1 
p < 0.001 
Blood 
Pressure 
Yes 
No 
41 (61.2%) 
26 (38.8%) 
64 (97.0%) 
2 (3.0%) 
χ
2 
= 25.60 
df = 1 
p < 0.001 
Bowel 
Habits 
Yes 
No 
0 (0%) 
67 (100.0%) 
53 (80.3%) 
13 (19.7%) 
χ
2 
= 89.45 
df = 1 
p < 0.001 
Weight Yes 
No 
32 (47.8%) 
35 (52.2%) 
62 (93.9%) 
4 (6.1%) 
χ
2 
= 34.21 
df = 1 
p = 0.0001 
Waist Yes 
No 
0 (0%) 
67 (100.0%) 
47 (71.2%) 
19 (28.8%) 
χ
2 
= 73.79 
df = 1 
p < 0.001 
‡ Fisher’s Exact test 
* = No statistics computed because pre- and post-intervention data are constant 
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ECG and ECHO 
Current guidelines recommend that ECG and ECHO be monitored every 6 
months62,110,111. The ECG and ECHO data for the pre- and post-interventional audits 
were obtained from patients’ clinical notes and computer records (Table 6). For ECG 
it found that the increase in monitoring from 22% pre-intervention to 58% post-
intervention was significant. The ECHO data show that while an improvement was 
noted in the post-intervention audit it was not large enough to be regarded significant 
(p= 0.059). 
 
 
Table 6: Frequency of ECG and ECHO every 6 months 
 Pre-intervention 
Audit 
(Audit 1) 
n, (%) 
Post-intervention 
Audit 
(Audit 2) 
n, (%) 
 
Significance† 
ECG Yes 
No 
14 (21.5%) 
51 (78.5%) 
38 (57.6%) 
28 (42.4%) 
χ
2 
= 18.92 
df = 3 
p < 0.001 
ECHO Yes 
No 
18 (27.3%) 
48 (72.7%) 
30 (45.5%) 
36 (54.5%) 
χ
2 
= 5.67 
df = 2 
p = 0.059 
† Pearson Chi-Square Test 
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The Prescribing Audit 
The prescribing audit concentrated on the proper completion and submission of all 
documentation that need to be sent to the pharmacy for obtaining a supply of 
clozapine 
At the study site, the following documents are required to be presented to the 
pharmacy for clozapine dispensing: 
 a prescription for clozapine 
 the patient’s medication chart 
 the patient’s blood count form 
 a copy of the haematology results showing the latest WCC and NC 
The pre- and post-interventional data for the documentation are presented in Table 7. 
The data indicates that the requirement for the presentation of these documents is 
being adhered to most of the time with a slight improvement being noted, post-
intervention. 
 
Table 7: Documents presented for dispensing 
 Pre-intervention 
Audit 
(Audit 1) 
n, (%) 
Post-intervention 
Audit 
(Audit 2) 
n, (%) 
 
Significance† 
Prescription 
 
Yes 
No 
66 (98.5%) 
1 (1.5%) 
66 (100%) 
0 
χ
2 
= 0.99 
df = 1 
p = 1.00 
Medication 
Chart  
Yes 
No 
67 (100%) 
0 
66 (100%) 
0 
* 
 
Blood Count 
Form  
Yes 
No 
66 (98.5%) 
1 (1.5%) 
66 (100%) 
0 
χ
2 
= 0.99 
df = 1 
p = 1.00 
Haematology 
Results 
Yes 
No 
59 (88.1%) 
8 (11.9%) 
64 (97.6%) 
2 (3.03%) 
χ
2 
= 3.80  
df = 1  
p = 0.10 
† Pearson Chi-Square Test 
* = No statistics computed because pre- and post-intervention data are constant 
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The Clozapine Prescription 
There was an overall improvement in adherence to the proper completion of all 
clozapine prescriptions sent to the pharmacy for dispensing as shown in Table 8. The 
most noteworthy changes were an increase in patients’ ID labels being attached to the 
prescriptions, inclusion of the route and duration and a reduction of transcription 
errors. 
Table 8: Results of pre- and post-intervention audit of Clozapine Prescriptions 
handed in to the pharmacy for dispensing during the study period 
 Pre- 
intervention 
Audit 
n, (%) 
Post-
intervention 
Audit 
n, (%) 
 
Significance† 
 
Patient ID label attached Yes 
No 
59 (88.1%) 
8 (11.9%) 
66 (100%) 
0 
χ
2 
=  7.28 
df = 1 
p = 0.01 
Correct ID label match 
for medication chart 
Yes 
No 
62(73.0%) 
4 (4.7%) 
66 (100%) 
0 
χ
2 
= 5.12 
df = 2 
p = 0.08 
Prescription legible Yes 
No 
67 (100%) 
0 
66 (100%) 
0  
*  
Drug 
 
Yes 
No 
66 (100%) 
0 
66 (100%) 
0 
*  
Dose 
 
Yes 
No 
66 (100%) 
0 
66 (100%) 
0 
*  
Route Yes 
No 
43 (64.2%) 
24 (35.8%) 
66 (100%) 
0 
χ
2 
= 28.85 
df = 1 
p < 0.001 
 
Frequency 
Yes 
No 
66 (98.5%) 
1 (1.5%) 
66 (100%) 
0 
χ
2 
= 0.10 
df = 1 
p = 1.000 
 
Prescription 
identical to 
the 
medication 
chart for the 
following 
 
Duration 
Yes 
No 
59 (88.1%) 
6 (8.9%) 
66 (100%) 
0 
χ
2 
= 9.51 
df = 1 
p = 0.003 
Prescription dated 
 
Yes 
No 
67 (100%) 
0 
66 (100%) 
0 
*  
Prescription signed Yes 
No 
67 (100%) 
0 
66 (100%) 
0 
*  
Transcription errors Yes 
No 
6 (8.9%) 
61 (91.1%) 
0 
66 (100%) 
χ
2 
= 6.39 
df = 1 
p = 0.01  
† Pearson Chi-Square Test 
* = No statistics computed because pre- and post-intervention data are constant 
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The Blood Count Form 
The data in Table 9 indicate that although there was essentially no change in some 
parameters that were measured, there was a general improvement in the completion of 
the blood count form after the intervention. Based on the data improvements were 
observed with more CPNs being clearly written and a reduction in the number of 
CPNs being incorrectly written. The parameters “All fields completed” and “Form 
signed by prescriber” remained constant at 100% pre- and post intervention. The 
data regarding the “Form completed by prescriber” parameter indicate that there 
was no improvement with this requirement as it remained a constant at about 90% 
pre- and post intervention.  
 
 
Table 9: Results of pre- and post-intervention audit of Blood Count Forms 
handed in to the pharmacy during the study period 
 Pre- 
intervention 
Audit 
(Audit 1) 
n, (%) 
Post-
intervention 
Audit 
(Audit 2) 
n, (%) 
 
Significance† 
Form completed by 
prescriber 
Yes 
No 
62 (92.5%) 
5 (7.5%) 
60 (90.9%) 
6 (9.1%) 
χ
2 
=0.40  
df = 1 
p = 0.56 
All fields completed Yes 
No 
67 (100%) 
0 
66 (100%) 
0 
* 
CPN clearly written Yes 
No 
62 (92.5%) 
5 (7.5%) 
66 (100%) 
0 
χ
2 
= 5.12 
df = 1 
p = 0.06 
CPN correct Yes 
No 
60 (89.6%) 
7 (10.4%) 
65 (98.5%) 
1 (1.5%) 
χ
2 
= 4.70 
df = 1 
p =0.06 
Form signed by 
prescriber  
Yes 
No 
67 (100%) 
0 
66 (100%) 
0 
* 
† Pearson Chi-Square Test 
* = No statistics computed because pre- and post-intervention data are constant 
CPN = Clozapine patient number 
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The Medication Chart 
A comparison of both the audits in Table 10 show that there was an increase in the 
practice of writing the patient’s CPN on the medication chart (Appendix H) in the 
post-interventional audit signifying an improvement in adherence to local clozapine 
recommendations. 
 
The other aspects of the medication chart that were measured with the exception of 
“Clinical pharmacist check” remained stable with little or no improvements being 
noted. The results of “Patient ID label attached” and “Correct ID match for 
prescription” which were found to be good in the pre-intervention audit improved 
slightly to reach 100% compliance in the post-intervention audit. 
 
Table 10: Results of pre- and post-intervention audit of Medication Charts 
handed in to the pharmacy for clozapine dispensing during the study period 
 Pre- 
intervention 
Audit 
(Audit 1) 
n, (%) 
Post-
intervention 
Audit 
(Audit 2) 
n, (%) 
 
Significance† 
Patient ID label 
attached 
Yes 
No 
64 (95.5%) 
3 (4.5%) 
66 (100%) 
0 
χ
2 
= 3.02 
df = 1 
p = 0.24 
Correct ID label 
match for 
prescription 
Yes 
No 
64 (95.5%) 
3 (4.5%) 
66 (100%) 
0 
χ
2 
= 3.02 
df = 2 
p = 0.22 
CPN on medication 
chart 
Yes 
No 
25 (37.3%) 
42 (62.7%) 
43 (65.2%) 
24 (36.4%) 
χ
2 
= 10.31 
df = 1 
p = 0.002 
Medication order 
legible 
Yes 
No 
67 (100%) 
0 
66 (100%) 
0 
* 
Clinical pharmacist 
check done 
Yes 
No 
62 (92.5%) 
5 (7.5%) 
55 (83.3%) 
11 (16.7%) 
χ
2 
= 2.66 
df = 1 
p =0.012 
Missed doses Yes 
No 
14 (20.9%) 
53 (79.1%) 
20 (30.3%) 
46 (69.7%) 
χ
2 
= 1.55 
df = 1 
p =0.24 
† Pearson Chi-Square Test 
CPN = Clozapine patient number 
ID label = Identification label 
* = No statistics computed because pre- and post-intervention data are constant 
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Haematology Results 
The pre-intervention audit revealed that there were 5 cases where blood older than 48 
hours was used in writing up the blood count form and 6 instances each of incorrect 
reporting of WCC and NC as shown in Table 11. No errors linked to the haematology 
results were recorded in the post-intervention audit, which represents a marked 
improvement. 
 
 
Table 11: Results of pre- and post-intervention audit of Haematology Results 
handed in to the pharmacy during the study period 
 Pre- 
intervention 
Audit 
(Audit 1) 
n, (%) 
Post-
intervention 
Audit 
(Audit 2) 
n, (%) 
 
Significance† 
 
Blood sample 
collected within 48 
hours 
Yes 
No 
62 (92.5%) 
5 (7.5%) 
66 (100%) 
0 
χ
2 
= 5.12 
df = 1 
p = 0.06 
WCC result 
correctly transcribed  
Yes 
No 
61 (91.0%) 
6 (9.0%) 
66 (100%) 
0 
χ
2 
= 6.19  
df = 1 
p = 0.03 
NC correctly 
transcribed 
Yes 
No 
61 (91.0%) 
6 (9.0%) 
66 (100%) 
0 
χ
2 
= 6.19 
df = 1 
p = 0.03 
† Pearson Chi-Square Test 
 
 
 
 
 
 
 
 
 
 
 
 
 
  40 
Clozapine Dose and Serum Level Monitoring 
To check the level of adherence of all prescribers’ to the recommended dosing 
guidelines for clozapine, the dose of clozapine that was prescribed in each instance 
was recorded and to assess whether patients serum levels of clozapine were within 
acceptable limits, the serum levels of clozapine for all patients were recorded. The 
change in clozapine dose was assessed pre- and post-intervention. The amount of 
clozapine prescribed increased significantly (paired-t = -2.10, df = 61, p = 0.039) from 
a mean dose (±SD) of 550mg (± 245mg) pre-intervention to a mean dose (±SD) of 
563mg (±248mg) post intervention (Table 12). The serum clozapine was also assessed 
pre- and post-intervention. Information for this variable was available for 43 patients. 
An increase in the serum clozapine was observed but it was not significant (p = 0.38) 
(Table 12). 
 
 
Table 12: Clozapine Dose and Serum levels 
  
Mean  
 
N 
 
SD 
 
t 
 
df 
 
Significance 
(2-tailed) 
Pair 
1 
Dose(mg) audit1 
Dose(mg) audit 2 
550.4 
562.9 
62 
62 
±245.3 
±247.6 
-
2.104 
 
61 0.04 
Pair 
2 
Serum(µg/L)audit1 
Serum(µg/L)audit 2 
560.5 
582.3 
43 
43 
±228.7 
±210.9 
-
0.875 
42 0.39 
SD = Standard deviation 
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5 DISCUSSION 
The objectives of this study were firstly to develop a clozapine decision support tool 
(CDST) and secondly to assess the impact of the CDST on the level of clinician 
adherence to the prescribing and monitoring guidelines for clozapine. The main 
finding of the assessment was that there was an overall improvement in adherence to 
the guidelines by clinicians with highly significant improvements noted in monthly 
physical health observations and 6 monthly ECG monitoring.  
 
Baseline, initiation and weekly monitoring 
Four patients were commenced on clozapine therapy before the intervention and 
another 4 were commenced post-intervention. Although the sample size in each 
instance was too small for the results to be subjected to meaningful statistical analysis, 
a general improvement in adherence by clinicians to the baseline, initiation and up-
titration phase monitoring recommendations was observed. The small number of 
patients who were commenced on clozapine therapy in both time periods was a 
shortcoming of this study as increasing the time allocated for data collection before 
and after intervention would have allowed for greater numbers of patients 
commencing treatment which in turn would have made the results more meaningful. 
Attention needs to be drawn to the avoidance of checking bowel habits of patients by 
nurses as evidenced by the results of the audit. A possible reason for the low 
adherence to the bowel habit question is that when nursing care, across all Australian 
facilities similar to The Park, changed from a nurse initiated and directed care 
approach to a recovery model of service delivery in 2000 it became the responsibility 
of  the patient to report such things as constipation or diarrhoea. This is in direct 
conflict with the clozapine guideline requirement of monitoring patients’ bowel habits 
and will need to be addressed at a much higher level and on a broader scale. 
Nevertheless the issue was addressed at the study site during the intervention phase 
which led to a major change in clinician adherence to this guideline recommendation 
resulting in 100% compliance.      
 
Where adherence to guidelines by clinicians was high to start with as depicted in 
Tables 5, 7, 8, 9 and 10, the significance of these parameters (depicted by an asterisk) 
could not be computed because little or no change was observed in the post-
intervention audit due to the ceiling effect. 
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Monthly monitoring 
The statistically significant increase in monthly monitoring of patients’ physical 
health by clinicians can be attributed to the introduction of a physical health 
monitoring prompt (Appendix F) in the patients’ clinical notes. At the time of its 
introduction, all clinicians were informed that completion and submission of this form 
was mandatory for every patient for whom a clozapine prescription is written. The 
expected outcome of 100% monitoring of all patients’ physical health was never 
realised, in part because of random refusal by different patients to yield to some or all 
of these physical health checks at different times. Another reason for non-adherence 
to monitoring these parameters is the lack of apparent interest by some clinicians in 
completing these health checks as evidenced by remarks such as “patient refused” 
written across the forms of all patients in a particular shift. Patients in seclusion are 
another barrier to completion of the health check procedure as they are often difficult 
to interact and communicate with and there is the ever present danger of the patient 
becoming violent. Clinicians have also complained of the lack of equipment such as a 
measuring tape for waist measurement at the time when it is needed. Nevertheless the 
overall outcome for the monthly physical health monitoring of patients was very 
good. 
 
The monitoring of bowel habits and waist measurements, which were not being done 
at all pre-intervention, were recorded at 80% and 71% respectively post-intervention. 
The use of similar prompts for clinicians in a mental health setting have been included 
in a report on Audit of Compliance with NICE Clinical Guidelines on Schizophrenia 
in 2008 and more recently by Gonzalez et al 201013,128. The latter study focussed on 
assessing and improving the routine blood testing of prescribed antipsychotics in an 
out-patient setting13. The finding that monitoring was low was presented to the 
prescribers and at the same time it was suggested that physical health assessments of 
patients be increased. The study showed that after the intervention which included the 
introduction of a simple one page monitoring prompt, routine blood monitoring and 
physical health monitoring improved significantly thereby resulting in a significant 
increase in the level of clinician adherence to the guidelines13. Interventions, whether 
verbal or via a prompt, have been shown to be useful in improving practice14,15,16,129. 
In a recent quality improvement project by a mental health pharmacist, to increase the 
level of awareness of staff on the risks associated with clozapine therapy at a hospital 
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in New Zealand various strategies were employed129. Interventions included the 
creation of a patient specific clozapine folder, education sessions and discussions with 
the nurses on the use of the folder, a fortnightly in-service on clozapine updates and 
accreditation of nurses129. Post intervention data showed that there was an increase in 
nurse awareness of: 
 the significant side effects of clozapine 
 baseline parameters that have to be measured before initiating clozapine 
 the importance of conducting regular physical monitoring 
 important drug interactions with clozapine 
 the administrative requirements related to the registration of new patients for 
clozapine therapy 
 
The intervention strategies of education sessions for the clinicians as well as the 
introduction of a decision support tool and a physical health monitoring prompt used 
in this study are very similar to those used in the quality improvement project 
discussed above. The essential difference between these two studies was the fact that 
the Kanniah project only targeted nurses while this study targeted all clinicians 
involved in caring for patients on clozapine therapy.  
 
           
 
ECG and ECHO 
It is recommended that ECG and ECHO be performed at least every 6 months on 
patients who are being treated with clozapine because of the serious cardiac related 
side effects of myocarditis and cardiomyopathy62. A comparison of pre- and post-
intervention data for ECG and ECHO reveals that there is an overall increase in the 
number of these recommended tests being performed. This increase in number of tests 
signifies an improvement on adherence to recommended guidelines by clinicians.  
 
The increase in adherence to the guidelines can be attributed to the introduction of the 
CDST and the in-house clinician education sessions that were conducted at the time 
of roll out of the intervention. The ECG is an easy test to perform compared to an 
ECHO and while ECGs are performed on-site ECHOs are performed in a specialized 
setting at a hospital 25km away and have to be booked in advance. These may be the 
  44 
reasons for more ECGs than ECHOs being performed during this study period. 
Another reason for this discrepancy is the random refusal by some patients to subject 
themselves to these ongoing tests. If a patient consistently refuses to have these tests 
done then the clinicians are obliged to consider changing to another antipsychotic as 
patient co-operation to ongoing monitoring is essential.  
 
 
Clozapine Dose and Serum Clozapine level 
A significant increase in the dose of clozapine post-intervention did not translate into 
a significant increase in the serum clozapine level. This finding is probably due to the 
increase in dose of patients in the up-titration phase of treatment. Current dosing 
guidelines state that the usual daily dose can range from 200 mg to 900 mg and that 
the serum threshold for therapeutic effect is 370 - 420 µg/L130. An increase in dose up 
to a maximum of 900 mg is allowed if there is failure to respond in this serum 
concentration range130. Compliance by clinicians to the dosing guideline was very 
good to start with and was constant in both audits. There was non-adherence to the 
dosing guidelines for 2 (2.9%) patients pre-intervention and 3 (4.5%) patients post-
intervention, all of whom were receiving doses in excess of 900 mg per day. The 
rapid metabolism of the drug in certain patients due to genetic factors and cigarette 
smoking may require daily doses in excess of the 900 mg licensed maximum up to 
1400 mg/day131. The three patients in the post-intervention audit were receiving doses 
of 1000mg, 1200mg and 1500mg respectively. While this is not in keeping with 
dosing guidelines current evidence justifies its use, as stated above, in specific 
circumstances. 
 
 
The Prescribing Audit 
Strict controls were already in place before the commencement of this study for the 
documentation requirements related to the dispensing process. This resulted in good 
compliance; therefore the pre- and post-interventional audits did not yield results of 
any significance. There were however some significant improvements on the part of 
the prescribers’ with the completion of these documents. Improvements with 
prescription writing included;  
 
  45 
1. an increase in: 
a. the attachment of patient ID labels from 88% to 100% 
b. the writing of the route and duration from 43% and 59% respectively 
to 100% in both cases, and 
2.   a decrease in transcription errors from 8.9% to zero. 
 
The reduction in the number of errors associated with the patients’ CPN on the blood 
count form is important because of the clinical consequences in the event that 
patients’ blood results are inadvertently mixed. There was an improvement in the 
practice of writing the patient’s CPN on all active medication charts belonging to 
patients on clozapine therapy. A correct CPN on the front cover of the medication 
chart (Appendix H) is of assistance to the prescriber in that it reduces the chances of 
mixing of blood results or incorrect doses being prescribed at the time of writing a 
blood count form or a clozapine prescription respectively. The dispensing pharmacist 
uses the haematology results to check the age of the blood sample and to establish 
whether the blood count form that was completed by the prescriber was without any 
errors. The reporting of WCC and NC is mandatory for every clozapine dispensing. 
The blood that is used for this assay must not be greater than 48 hours old at the time 
of dispensing. If the blood sample is older than 48 hours the dispensing pharmacist is 
obliged to reduce the quantity of clozapine dispensed by one day for every day 
beyond 48 hours. The improvements in sample age as well as with WCC and NC 
post-intervention are probably due to the in-service education and training sessions 
that were held in all clinical areas during the roll out of the CDST as the intervention     
 
Adherence to guidelines 
Some of the knowledge that is acquired by staff during their stay in a ward or facility 
is tacit in nature and is lost when that clinician is moved to another ward or facility. 
New staff coming in may have to be up skilled or retrained possibly resulting in the 
observed poor adherence to guideline recommendations during this period of training. 
The prescribing of clozapine requires specialised training and up skilling of 
prescribers that goes beyond the five minutes spent on clozapine prescribing during 
the ten minute orientation that is given to all registrars at the start of their rotation at 
The Park.  The CDST is a pleasantly coloured, tangible document that has been 
strategically placed in all clinical areas to positively influence the adherence to 
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guidelines by clinicians. Pre-interventional adherence to guidelines for some 
parameters was high to start with, so slight improvements were difficult to prove 
using statistical analysis.  
The potential benefits associated with adherence to prescribing and monitoring 
guidelines by clinicians is a minimisation of the risks such as agranulocytosis, 
myocarditis and cardiomyopathy associated with clozapine therapy. In addition there 
is the associated benefit of early identification and treatment of adverse effects such 
as hypertension, hyperlipidaemia, constipation and diabetes. Such early identification 
of potential adverse effects can only be achieved if the basic monitoring guidelines 
are adhered to by clinicians. The pre-interventional audit in this study indicates that 
physical health monitoring of patients by clinicians was poor (Tables 2 – 6). The 
probability that this poor adherence to basic monitoring guidelines is representative of 
current practice at other mental health facilities is strengthened by the North 
Derbyshire Mental Health audit in 2009, which found that at the time of admission 
only 67% of patients were examined according to the guidelines12.  
 
The observed improvements in adherence by clinicians to monitoring guidelines in 
this study can be attributed to the level of clinician awareness of current guideline 
recommendations. This is in keeping with the findings of a similar study that 
measured the effect of an intervention which concentrated on improving clinician 
awareness to baseline and physical health monitoring requirements129. The study 
showed that the increase in awareness was consistent with an increase in post-
interventional monitoring129. 
 
Clozapine is a section 189 regulated restricted drug and is not available in the 
community setting. Currently community-based patients get their supply of clozapine 
from hospital pharmacies and are subject to the same monitoring and treatment 
guidelines as in-patients.  
 
Limitations and future research 
 
The time constraint was a limitation of this study. This led to a small sample size for 
patients in the initiation phase of treatment in both the pre-intervention and post-
intervention periods. Only 4 patients commenced clozapine treatment in each of the 
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audit periods (Table1). As the t-test requires 5 samples or more for statistical analysis 
to yield meaningful results the data associated with the initiation of clozapine in these 
4 patients in each audit period was not subjected to statistical analysis. Future 
researchers on this subject could increase the pre- and post-interventional data 
collection periods thereby allowing for the inclusion of greater numbers of patients 
commencing clozapine therapy. 
 
Future research could also explore clinician perceptions on the usefulness of the tool 
and the tool’s sustainability. Based on the success of the physical health monitoring 
prompt, future research could also assess whether strategically placed prompts at 
different levels in the treatment pathway would improve the level of clinician 
adherence to guidelines in all aspects of clozapine therapy. And finally future research 
could examine the level of clinician adherence to guidelines when treating community 
based patients on clozapine therapy. 
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6 CONCLUSION 
The intervention strategies improved clinician knowledge base and brought about a 
significant change in awareness and understanding of clozapine guidelines and the 
associated monitoring requirements. There was an overall improvement in adherence 
to the prescribing and monitoring guidelines for clozapine therapy with statistically 
significant improvements in monthly physical health monitoring, ECG testing and 
correct and consistent reporting of blood results.  
  
The intervention (CDST) will be kept in place and will be ongoing as will be the 
requirement for submission of physical health observations using the physical health 
prompt. The adoption of this quality improvement process by other mental health 
facilities should improve the quality of care with the potential for better patient 
outcomes.  
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